NCT03888222View on ClinicalTrials.gov

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

August 27, 2021

Study Completion Date

August 27, 2021

Conditions
Dementia With Lewy Bodies
Interventions
DRUG

Placebo Oral Tablet

"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."

DRUG

Bosutinib Oral Tablet

Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .

Trial Locations (1)

20007

MedStar Georgetown University Hospital, Washington D.C.

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

Georgetown University

OTHER

NCT03888222 - Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies | Biotech Hunter | Biotech Hunter